期刊
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
卷 77, 期 12, 页码 2373-2377出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/gerona/glab358
关键词
Geroscience; Healthspan; Insulin sensitivity; Mitochondria; Skeletal muscle
资金
- National Institute on Aging [T32AG052363, R01 AG064951]
- Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002373]
- Oklahoma Shared Clinical and Translational Resources [U54GM104938]
- Dexcom, Inc.
Metformin treatment has varied effects on insulin sensitivity and skeletal muscle mitochondrial adaptations in older adults, depending on their initial insulin status. This clinical trial aims to determine the impact of metformin monotherapy on metabolic health and cellular mechanisms involved in aging, independent of exercise. Findings from this trial will inform larger Phase 3 clinical trials exploring aging as a treatment indication for metformin.
The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans. While there is extensive epidemiological support for the health benefits of metformin in patient populations, it is not clear if these protective effects apply to those free of age-related disease. Our previous data in older adults without diabetes suggest a dichotomous change in insulin sensitivity and skeletal muscle mitochondrial adaptations after metformin treatment when co-prescribed with exercise. Those who entered the study as insulin-sensitive had no change to detrimental effects while those who were insulin-resistant had positive changes. The objective of this clinical trial is to determine if (a) antecedent metabolic health and (b) skeletal muscle mitochondrial remodeling and function mediate the positive or detrimental effects of metformin monotherapy, independent of exercise, on the metabolism and biology of aging. In a randomized, double-blind clinical trial, adults free of chronic disease (n = 148, 40-75 years old) are stratified as either insulin-sensitive or resistant based on homeostatic model assessment of insulin resistance (<= 2.2 or >= 2.5) and take 1 500 mg/day of metformin or placebo for 12 weeks. Hyperinsulinemic-euglycemic clamps and skeletal muscle biopsies are performed before and after 12 weeks to assess primary outcomes of peripheral insulin sensitivity and mitochondrial remodeling and function. Findings from this trial will identify clinical characteristics and cellular mechanisms involved in modulating the effectiveness of metformin treatment to target aging that could inform larger Phase 3 clinical trials aimed at testing aging as a treatment indication for metformin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据